Disease · MONDO_0005520
rickets
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. rickets. Diseases, record MONDO_0005520. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005520
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Other names
- Weak and soft bones, active rickets, rachitis, rickets (disease), vitamin D hydroxylation-deficient rickets, vitamin D-dependent rickets
- Open Targets
Drugs8
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| SEOCALCITOL | CHEMBL1908376 | Small molecule | Phase 3 | TTD | 1 | 0 | 0 | Drugs and targets |
| CHOLECALCIFEROL | CHEMBL1042 | Small molecule | Phase 2/3 | ClinicalTrials.gov | 5 | 5 | 5 | Drugs and targets |
| ASCORBIC ACID | CHEMBL196 | Small molecule | Phase 2/3 | ClinicalTrials.gov | 1 | 1 | 0 | Drugs and targets |
| CURCUMIN | CHEMBL140 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| PIPERINE | CHEMBL43185 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| ERGOCALCIFEROL | CHEMBL1536 | Small molecule | Phase 1 | ClinicalTrials.gov | 3 | 3 | 3 | Drugs and targets |
| CALCITRIOL | CHEMBL846 | Small molecule | Early phase 1 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| RISEDRONIC ACID | CHEMBL923 | Small molecule | Unknown | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
Targets2
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| VDR | Vitamin D3 receptor | 4 | Vitamin D receptor agonist | Phase 3 | https://conductscience.org/library/genes/7421 | Drugs and targets |
| FDPS | Farnesyl pyrophosphate synthase | 1 | Farnesyl diphosphate synthase inhibitor | Unknown | https://conductscience.org/library/genes/2224 | Drugs and targets |
Trials9
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02802449 | To Study the Nutri-Genomic Response of Vit-D Supplementation in African-Americans | Not applicable | 330 | 2018-05-24 | Hypovitaminosis D | CHOLECALCIFEROL | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT02881957 | Hypovitaminosis D in Neurocritical Patients | Phase 2/3 | 274 | 2020-08-17 | Craniocerebral Trauma, Intracranial Aneurysm, Brain Neoplasms, Spinal Cord Injuries, Seizures, Meningitis, Stroke, Intracranial Hemorrhages, Critical Illness, Vitamin d Deficiency | CHOLECALCIFEROL | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT00948298 | Effect of Vitamin D3 on Vascular Function | Not applicable | 130 | 2018-07-17 | Vitamin D Deficiency | CHOLECALCIFEROL | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT01974245 | Supplementation With Cholecalciferol in Dialysis Patients | Phase 2 | 55 | 2014-12-12 | Chronic Kidney Disease | CHOLECALCIFEROL | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT06481111 | Prospective Monocentric Registry of Patients Undergoing Vitamin D Treatment at San Raffaele Hospital | 1,000 | Hypovitaminosis D | ERGOCALCIFEROL | Open Targets' reading of its record | ClinicalTrials.gov | ||
| NCT05430087 | Vitamin D and Curcumin Piperine Attenuates Disease Activity and Cytokine Levels in Systemic Lupus Erythematosus Patients | Phase 2 | 45 | Systemic Lupus Erythematosus | CHOLECALCIFEROL, CURCUMIN, PIPERINE | Open Targets' reading of its record | ClinicalTrials.gov | |
| NCT05346419 | Antiresorptive Effect of Treatment With Risedronate and Vitamin D in Postmenopausal Patients | Not applicable | 33 | Postmenopausal Osteoporosis, Hypovitaminosis D, Hyperparathyroidism | ERGOCALCIFEROL, RISEDRONIC ACID | Open Targets' reading of its record | ClinicalTrials.gov | |
| NCT03356730 | Effect of Vitamin D Replacement on Bone Healing in Mini-dental Implants | Phase 1 | 20 | Deficiency, Vitamin D | ERGOCALCIFEROL | Open Targets' reading of its record | ClinicalTrials.gov | |
| NCT03748966 | Calcitriol Monotherapy for X-Linked Hypophosphatemia | Early phase 1 | 16 | X-linked Hypophosphatemia, Hypophosphatemic Rickets, Hypophosphatemic Rickets, X-Linked Dominant | CALCITRIOL | Its record names the disease | ClinicalTrials.gov |
Comparisons in its trials13
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| 25 Hydroxy-Vitamin D3 or [25 (OH) D3] vs Placebo: deaths from any cause | 0 of 219 | 0 of 111 | 330 | NCT02802449 | Trial comparisons |
| 25 Hydroxy-Vitamin D3 or [25 (OH) D3] vs Placebo: serious adverse events | 0 of 219 | 1 of 111 | 330 | NCT02802449 | Trial comparisons |
| Vitamin D3 vs Placebo: Number of Participants With Sepsis | 2 of 134 | 3 of 133 | 267 | NCT02881957 | Trial comparisons |
| Vitamin D3 vs Placebo: In-hospital Mortality | 11 of 134 | 13 of 133 | 267 | NCT02881957 | Trial comparisons |
| Vitamin D3 vs Placebo: Number of Participants With Deep Vein Thrombosis | 8 of 134 | 3 of 133 | 267 | NCT02881957 | Trial comparisons |
| Vitamin D3 vs Placebo: Number of Participants With Study Drug Related Adverse Events | 0 of 134 | 0 of 133 | 267 | NCT02881957 | Trial comparisons |
| Vitamin D3 vs Placebo: Number of Participants With Pneumonia | 16 of 134 | 14 of 133 | 267 | NCT02881957 | Trial comparisons |
| Vitamin D3 vs Placebo: Number of Participants With Urinary Tract Infection | 9 of 134 | 6 of 133 | 267 | NCT02881957 | Trial comparisons |
| Vitamin D3 vs Placebo: deaths from any cause | 11 of 134 | 13 of 133 | 267 | NCT02881957 | Trial comparisons |
| Vitamin D3 vs Placebo: serious adverse events | 0 of 134 | 0 of 133 | 267 | NCT02881957 | Trial comparisons |
1 to 10 of 13
See all 13 comparisons in its trialsPapers from its trials33
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0005520
GET https://conductscience.org/api/diseases/v1/MONDO_0005520/papers?page=2